It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Androgen independency is associated with poor prostate cancer (PCa) survival. Here we report that silencing of transglutaminase-2 (TG2) expression by CRISPR-Cas9 is associated with upregulation of androgen receptor (AR) transcription in PCa cell lines. Knockout of TG2 reversed the migratory potential and anchorage independency of PC3 and DU145 cells and revealed a reduced level of mucin-1 (MUC1) RNA transcript through unbiased multi-omics profiling, which was restored by selective add-back of the truncated TG2 isoform (TGM2_v2). Silencing of AR resulted into increased MUC1 in TG2KO PC3 cells showing that TG2 affects transcriptional regulation of MUC1 via repressing AR expression. Treatment of PC3 WT cell line with TG2 inhibitor ZDON led to a significant increase in AR expression and decrease in MUC1. ZDON also blocked the formation of MUC1-multimers labelled with TG amine-donor substrates in reducing conditions, revealing for the first time a role for TG2, which we show to be externalised via extracellular vesicles, in MUC1 stabilisation via calcium-dependent transamidation. A specific antibody towards TGM2_v2 revealed its restricted nuclear location compared to the canonical long form of TG2 (TGM2_v1), which is predominantly cytosolic, suggesting that this form contributes to the previously suggested TG2-mediated NF-κB activation and AR transcriptional repression. As TGM2_v2 transcription was increased in biopsies of early-stage prostate adenocarcinoma (PRAD) patients compared to subjects presenting inflammatory prostatitis, and total TG2 protein expression significantly increased in PRAD versus normal tissue, the role of TG2 and its truncated form as a prostate malignancy marker is suggested. In conclusion, this investigation has provided the first unbiased discovery of a novel pathway mediated by TG2 via MUC1, which is shown to contribute to androgen insensitivity and malignancy of PCa cells and be upregulated in PCa biopsies, with potential relevance to cancer immune evasion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Nottingham Trent University, School of Science and Technology, Centre for Health, Ageing and Understanding of Disease, Nottingham, UK (GRID:grid.12361.37) (ISNI:0000 0001 0727 0669); Staffordshire University, Department of Biological and Biomedical Sciences, Science Centre, School of Health, Science and Wellbeing, Stoke-on-Trent, UK (GRID:grid.19873.34) (ISNI:0000000106863366)
2 Nottingham Trent University, School of Science and Technology, Centre for Health, Ageing and Understanding of Disease, Nottingham, UK (GRID:grid.12361.37) (ISNI:0000 0001 0727 0669)
3 Nottingham Trent University, John van Geest Cancer Research Centre, Nottingham, UK (GRID:grid.12361.37) (ISNI:0000 0001 0727 0669)
4 Polyclinic Hospital University, Department of Human and Paediatric Pathology, Messina, Italy (GRID:grid.12361.37)
5 Polyclinic Hospital University, Department of Biomedical Sciences, Dental Sciences & Morpho-Functional Imaging, Messina, Italy (GRID:grid.12361.37)
6 Nottingham Trent University, School of Science and Technology, Centre for Health, Ageing and Understanding of Disease, Nottingham, UK (GRID:grid.12361.37) (ISNI:0000 0001 0727 0669); University of Bologna, Biological Sciences Department (BiGeA), Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)